As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of November 8, 2012.

Visit Pfizer.com/pipeline, Pfizer’s online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Pipeline Snapshot</td>
<td>4</td>
</tr>
<tr>
<td>Cardiovascular &amp; Metabolic Diseases</td>
<td>5</td>
</tr>
<tr>
<td>Inflammation &amp; Immunology</td>
<td>6</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>7</td>
</tr>
<tr>
<td>Oncology</td>
<td>8</td>
</tr>
<tr>
<td>Vaccines</td>
<td>9</td>
</tr>
<tr>
<td>Other Areas of Focus</td>
<td>10</td>
</tr>
<tr>
<td>Projects Discontinued Since Last Update</td>
<td>11</td>
</tr>
</tbody>
</table>
**Pfizer Pipeline Snapshot**

**Pfizer Pipeline Snapshot as of November 8, 2012**

- **8 programs advanced or are new**

- **3 programs advanced or are new**

- **8 projects discontinued since last update**

**Pfizer Pipeline Snapshot as of August 9, 2012**

- **8 programs advanced or are new**

- **Discovery Projects**

- **Phase 1** 25

- **Phase 2** 28

- **Phase 3** 17

- **In Reg.** 8

- **Total** 78

**Recent Approvals**

- **Xeljanz** (tofacitinib) for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate (U.S.)

- **Xalkori** for treatment of previously treated ALK-positive advanced non-small cell lung cancer (EU)

- **Bosulif** (bosutinib) for treatment of previously treated chronic myelogenous leukemia (U.S.)

- **Inlyta** (axitinib) for treatment of advanced renal cell carcinoma after failure of prior systemic treatment (EU)

**Pfizer Pipeline Snapshot as of August 9, 2012**

- **8 projects discontinued since last update**

**Pfizer Pipeline Snapshot as of November 8, 2012**

- **8 projects discontinued since last update**

**Recent Approval**

- **Lyrica** for treatment of central neuropathic pain due to spinal cord injury (U.S.)

**Pipeline represents progress of R&D programs as of November 8, 2012**

- Included are 59 NMEs, 17 additional indications, plus 2 biosimilars

**Pipeline represents progress of R&D programs as of August 9, 2012**

- Included are 65 NMEs, 20 additional indications, plus 2 biosimilars
<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Compound Name</th>
<th>Mechanism of Action (Phase 3 through regulatory approval)</th>
<th>Indication</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Viviant</td>
<td>Selective Estrogen Receptor Modulator</td>
<td>Osteoporosis Treatment and Prevention (U.S.)</td>
<td>Registration</td>
</tr>
<tr>
<td></td>
<td>Eliquis (apixaban)</td>
<td>Factor Xa Inhibitor</td>
<td>Prevention of Stroke and Systemic Embolism in patients with Nonvalvular Atrial Fibrillation (U.S./EU)</td>
<td>Registration</td>
</tr>
<tr>
<td></td>
<td>apixaban</td>
<td>Factor Xa Inhibitor</td>
<td>Venous Thromboembolism Prevention (U.S.)</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Eliquis (apixaban)</td>
<td>Factor Xa Inhibitor</td>
<td>Venous Thromboembolism Treatment</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Cardiovascular and Metabolic Diseases</td>
<td>PF-04971729</td>
<td>Factor Xa Inhibitor</td>
<td>Diabetes Mellitus-Type 2</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>RN316 (PF-04950615)</td>
<td>Factor Xa Inhibitor</td>
<td>Hypercholesterolemia (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-04937319</td>
<td>Factor Xa Inhibitor</td>
<td>Diabetes Mellitus-Type 2</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-00489791</td>
<td>Diabetic Nephropathy</td>
<td>Diabetes Mellitus-Type 2 (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>CVX 096 (PF-04856883)</td>
<td>Factor Xa Inhibitor</td>
<td>Diabetes Mellitus-Type 2</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-05231023</td>
<td>Factor Xa Inhibitor</td>
<td>Diabetes Mellitus-Type 2 (Biologic)</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-05175157</td>
<td>Factor Xa Inhibitor</td>
<td>Diabetes Mellitus-Type 2</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-05335810</td>
<td>Factor Xa Inhibitor</td>
<td>Hypercholesterolemia (Biologic)</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-06282999</td>
<td>Factor Xa Inhibitor</td>
<td>Acute Coronary Syndrome</td>
<td>Phase 1</td>
</tr>
<tr>
<td>Therapeutic Area</td>
<td>Compound Name</td>
<td>Mechanism of Action (Phase 3 through regulatory approval)</td>
<td>Indication</td>
<td>Phase</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------</td>
<td>------------------------------------------------------------</td>
<td>----------------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Inflammation and Immunology</td>
<td>tofacitinib (CP-690550)</td>
<td>JAK Inhibitor</td>
<td>Rheumatoid Arthritis (EU)</td>
<td>Registration</td>
</tr>
<tr>
<td></td>
<td>tofacitinib (CP-690550)</td>
<td>JAK Inhibitor</td>
<td>Psoriasis (Oral)</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>tofacitinib (CP-690550)</td>
<td>JAK Inhibitor</td>
<td>Ulcerative Colitis</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>PF-04171327</td>
<td></td>
<td>Rheumatoid Arthritis</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-05285401</td>
<td></td>
<td>Ulcerative Colitis (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>anrakinzumab (IMA-638)</td>
<td></td>
<td>Ulcerative Colitis (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-00547659</td>
<td></td>
<td>Crohn’s Disease (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-04236921</td>
<td></td>
<td>Crohn’s Disease, Lupus, *Rheumatoid Arthritis (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>tofacitinib (CP-690550)</td>
<td></td>
<td>Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis (Topical), Crohn’s Disease</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-06473871 (EXC 001)</td>
<td></td>
<td>Dermal Scarring</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PD-360324</td>
<td></td>
<td>Lupus (Biologic)</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-05280586</td>
<td></td>
<td>Rheumatoid Arthritis (Biosimilar)</td>
<td>Phase 1</td>
</tr>
</tbody>
</table>

*Note: Additional indications in Phase 1

New Molecular Entity | New Indication or Enhancement | Biosimilar
<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Compound Name</th>
<th>Mechanism of Action (Phase 3 through regulatory approval)</th>
<th>Indication</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>neuroscience &amp; pain</td>
<td>tafamidis meglumine</td>
<td>Transthyretin (TTR) Dissociation Inhibitor</td>
<td>Transthyretin familial amyloid polyneuropathy (U.S.)</td>
<td>Registration</td>
</tr>
<tr>
<td></td>
<td>Celebrex</td>
<td>COX-2</td>
<td>Chronic Pain (U.S.)</td>
<td>Registration</td>
</tr>
<tr>
<td></td>
<td>Remoxy</td>
<td>Mu-type opioid receptor (MOR-1) Agonist</td>
<td>Moderate to Severe Pain (U.S.)</td>
<td>Registration</td>
</tr>
<tr>
<td></td>
<td>ALO-02 Oxycodone-naltrexone core</td>
<td>Mu-type opioid receptor (MOR-1) Agonist</td>
<td>Moderate to Severe Pain</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Lyrica</td>
<td>Alpha-2 Delta Ligand</td>
<td>Peripheral Neuropathic Pain</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Lyrica</td>
<td>Alpha-2 Delta Ligand</td>
<td>CR (once a day dosing)</td>
<td>Phase 3</td>
</tr>
<tr>
<td>neuroscience &amp; pain</td>
<td>tanezumab</td>
<td>Nerve Growth Factor Inhibitor</td>
<td>OA Signs and Symptoms (Biologic)</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>PF-02545920</td>
<td>Schizophrenia</td>
<td></td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-03049423</td>
<td>Stroke Recovery</td>
<td></td>
<td>Phase 2</td>
</tr>
<tr>
<td>neuroscience &amp; pain</td>
<td>tanezumab</td>
<td>Chronic Pain (Biologic)</td>
<td></td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-05089771</td>
<td>Chronic Pain</td>
<td></td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-05236812 (AAB-003)</td>
<td>Alzheimer’s Disease (Biologic)</td>
<td></td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-04958242</td>
<td>Schizophrenia, Sensorineural Hearing Loss</td>
<td></td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-05212377 (SAM-760)</td>
<td>Alzheimer’s Disease</td>
<td></td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-05180999</td>
<td>Schizophrenia</td>
<td></td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-06273340</td>
<td>Acute and Chronic Pain</td>
<td></td>
<td>Phase 1</td>
</tr>
<tr>
<td>Therapeutic Area</td>
<td>Compound Name</td>
<td>Mechanism of Action (Phase 3 through regulatory approval)</td>
<td>Indication</td>
<td>Phase</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------</td>
<td>----------------------------------------------------------</td>
<td>------------</td>
<td>-------</td>
</tr>
<tr>
<td><strong>Oncology</strong></td>
<td>bosutinib</td>
<td>Abl and src-family kinase inhibitor</td>
<td>Treatment of Previously Treated Chronic Myelogenous Leukemia (EU)</td>
<td>Registration</td>
</tr>
<tr>
<td></td>
<td>dacomitinib</td>
<td>pan-HER Inhibitor</td>
<td>Previously Treated Advanced Non-Small Cell Lung Cancer</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Xalkori (crizotinib)</td>
<td>c-MET-ALK Inhibitor</td>
<td>ALK-Positive 1st and 2nd Line (supports full approval in the U.S.) Non-Small Cell Lung Cancer, *Cancer</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Inlyta (axitinib)</td>
<td>VEGF Tyrosine Kinase Inhibitor</td>
<td>Renal Cell Carcinoma Adjuvant (Asia only)</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Sutent</td>
<td>Multiple Tyrosine Kinase Inhibitor</td>
<td>Renal Cell Carcinoma Adjuvant</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>inotuzumab ozogamicin</td>
<td></td>
<td>Aggressive Non-Hodgkin’s Lymphoma (Biologic)</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>inotuzumab ozogamicin</td>
<td></td>
<td>Acute Lymphoblastic Leukemia (Biologic)</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Inlyta (axitinib)</td>
<td></td>
<td>Liver Cancer</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>dacomitinib</td>
<td></td>
<td>Cancer</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PD-0332991</td>
<td></td>
<td>1st Line Advanced Breast Cancer</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>CVX 060 (PF-04856884)</td>
<td></td>
<td>Renal Cell Carcinoma, *Cancer (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-05212384</td>
<td></td>
<td>Endometrial Cancer, *Cancer</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-03084014</td>
<td></td>
<td>Cancer</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-03446962</td>
<td></td>
<td>Cancer (Biologic)</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PD-0325901</td>
<td></td>
<td>Cancer (in combination with PF-05212384)</td>
<td>Phase 1</td>
</tr>
</tbody>
</table>

* Note: Additional indications in Phase 1
<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Compound Name</th>
<th>Mechanism of Action (Phase 3 through regulatory approval)</th>
<th>Indication</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology (cont’d)</td>
<td>PF-05082566</td>
<td>Cancer (Biologic)</td>
<td></td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-04605412</td>
<td>Cancer (Biologic)</td>
<td></td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-05280014</td>
<td>Metastatic Breast Cancer (Biosimilar)</td>
<td></td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-04449913</td>
<td>Acute Myelocytic Leukemia</td>
<td></td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>ACC-001 (PF-05236806)</td>
<td>Alzheimer’s Disease</td>
<td></td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>►MnB rLP2086 (PF-05212366)</td>
<td>Adolescent and Young Adult Meningitis B</td>
<td></td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF-06290510)</td>
<td>Staph Aureus</td>
<td></td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-05402536</td>
<td>Smoking Cessation</td>
<td></td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>►PF-06425090</td>
<td>Clostridium Difficile Colitis</td>
<td></td>
<td>Phase 1</td>
</tr>
</tbody>
</table>

- **New Molecular Entity**: New Indication or Enhancement
- **Biosimilar**: Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com
## Pfizer Pipeline – November 8, 2012 (cont’d)

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Compound Name</th>
<th>Mechanism of Action (Phase 3 through regulatory approval)</th>
<th>Indication</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Menopausal Vasomotor</td>
<td>bazedoxifene-conjugated estrogens</td>
<td>Tissue Selective Estrogen Complex</td>
<td>Menopausal Vasomotor Symptoms (EU)</td>
<td>Registration</td>
</tr>
<tr>
<td>Other Areas of Focus</td>
<td>Zithromax/chloroquine</td>
<td>5-OS Ribosome Inhibitor</td>
<td>Malaria</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Menopausal Vasomotor</td>
<td>bazedoxifene-conjugated estrogens</td>
<td>Tissue Selective Estrogen Complex</td>
<td>Menopausal Vasomotor Symptoms (U.S.)</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>bosutinib</td>
<td></td>
<td>Autosomal Dominant Polycystic Kidney Disease</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-00868554 (filibuvir)</td>
<td></td>
<td>Hepatitis C Virus</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>tofacitinib (CP-690550)</td>
<td></td>
<td>Transplant Rejection</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PH-797804</td>
<td></td>
<td>Chronic Obstructive Pulmonary Disease</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-06460031 (GMI-1070)</td>
<td></td>
<td>Vaso-occlusive crisis associated with Sickle Cell Disease</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PNU-100480</td>
<td></td>
<td>Tuberculosis</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>►RN6G (PF-04382923)</td>
<td></td>
<td>Age-Related Macular Degeneration (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-03715455</td>
<td></td>
<td>Chronic Obstructive Pulmonary Disease</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-05280602</td>
<td></td>
<td>Hemophilia (Biologic)</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-06252616</td>
<td></td>
<td>Muscular Dystrophies (Biologic)</td>
<td>Phase 1</td>
</tr>
</tbody>
</table>

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

New Molecular Entity

New Indication or Enhancement
<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Mechanism of Action (Phase 3 through regulatory approval)</th>
<th>Indication</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taliglucerase alfa</td>
<td>Enzyme Replacement Therapy</td>
<td>Type 1 Gaucher Disease (Biologic) (EU)</td>
<td>Registration</td>
</tr>
<tr>
<td>Xiapex (EU)</td>
<td>Clostridial Collagenase for Injection</td>
<td>Peyronie’s Disease (Biologic) (EU)</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Inlyta (axitinib)</td>
<td>VEGF Tyrosine Kinase Inhibitor</td>
<td>Advanced Renal Cell Carcinoma in treatment-naive patients</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Eraxis/Vfend</td>
<td>Beta-D Glucan Synthase Inhibitor, Cyp P450 Mediated Alpha-lanosterol Demethylation</td>
<td>Aspergillosis</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Eladur</td>
<td></td>
<td>Chronic Pain</td>
<td>Phase 2</td>
</tr>
<tr>
<td>PF-04691502</td>
<td></td>
<td>Endometrial Cancer, *Cancer</td>
<td>Phase 2</td>
</tr>
<tr>
<td>OAP-189 (PF-05212389)</td>
<td></td>
<td>Diabetes Mellitus-Type 2, Obesity (Biologic)</td>
<td>Phase 1</td>
</tr>
<tr>
<td>PF-03882845</td>
<td></td>
<td>Diabetic Nephropathy</td>
<td>Phase 1</td>
</tr>
</tbody>
</table>

*Note: Additional indications in Phase 1